S1. Multiple Myeloma and
S7. Stem Cell Transplantation and New Cellular Therapies
Date: 28th October 2026 (Wednesday)
Time: 13:00 (CET, Basel) | 08:00 (EDT, New York) | 20:00 (CST Asia, Beijing)
| Time (CET) |
Speaker | Title |
| Session 1. Multiple Myeloma | ||
| 13:00-13:10 |
Prof. Dr. Claudio Cerchione |
Welcome and Opening Remarks |
| 13:10-13:20 |
Prof. Dr. Claudio Cerchione |
Welcome by Session Chair |
| 13:20-13:50 |
Prof. Dr. Claudio Cerchione |
How I treat Multiple Myeloma |
| 13:50-14:30 |
Assoc. Prof. Renato Zambello |
Difficult to Treat Myeloma |
| 14:30-14:50 |
Prof. Dr. Fredrik Schjesvold |
Optimal treatment of myeloma, and what to do when options are lacking - A strategy talk |
|
Contributed Oral Presentations |
Session 1. Multiple Myeloma | |
| 14:50-15:05 |
Winnie Noe |
BCMA-directed CAR-T treatment for Refractory Multiple Myeloma |
| 15:05-15:20 |
Ellen Purcell |
Oxidative Phosphorylation and mTOR Activation Drive Transcriptomic Divergence in Extramedullary Multiple Myeloma |
| 15:20-15:35 |
Nemany A.N. Hanafy |
Optimizing soyasaponin–carbon quantum dots for targeting multiple myeloma cells as a natural-derived and cost-effective theranostic system |
| S7. Stem Cell Transplantation and New Cellular Therapies | ||
| 15:35-15:45 |
Prof. Dr. Aurelio Maggio |
Welcome by Session Chair |
| 15:45-16:25 | Prof. Dr. Andrea Bacigalupo Plenary Speaker |
Allogeneic HSCT for AML: the problem of post-transplant relapse |
| 16:25-16:55 |
Dr. John Tisdale |
Translating basic science discoveries to the first successful gene therapies for sickle cell disease, from concept to FDA approval |
| 16:55-17:25 |
Dr. Alessandro Busca |
Post-Transplant Cyclophosphamide(Ptcy) as the New Paradigm for Gvhd Prophylaxis in Allogeneic Stem Cell Transplantation: From Efficacy to Infectious Complications |
| Contributed Oral Presentations | S7. Stem Cell Transplantation and New Cellular Therapies | |
| 16:55-17:25 | Shruti Sandesh Morankar Selected Speaker |
Redefining the Treatment Continuum: A Toxicity- and Response-Adapted Framework for Sequencing Autologous CAR-T, Allogeneic Stem Cell Transplantation, and Bispecific T-Cell Engagers in Relapsed/Refractory Hematologic Malignancies |
S6. CML and Myeloproliferative Neoplasms and
Flash Poster Session
Date: 29th October 2026 (Thursday)
Time: 09:00 (CET, Basel) | 04:00 (EDT, New York) | 16:00 (CST Asia, Beijing)
| Time (CET) |
Speaker | Title |
| 09:00-09:10 |
Dr. Alessandro Lucchesi and Dr. Elisabetta Abruzzese |
Welcome by Session Chairs |
| 09:10-09:30 |
Dr. Ahmad Alabdulkarim |
Beyond JAK2: A Systematic Approach to the Differential Diagnosis of JAK2-Negative Erythrocytosis |
| 09:30-09:50 |
Dr. José Miguel Torregrosa-Díaz |
First-Line Combination Strategies in Myelofibrosis: Emerging Evidence, Evolving Questions |
| 09:50-10:10 |
Dr. Gianantonio Rosti |
The Present and Future of CML: Still Room for Improvement? |
| 10:10-10:30 |
Prof. A. Emre Eskazan |
The Dark Side of TKIs: The Price of Success |
|
Contributed Oral Presentations |
S6. CML and Myeloproliferative Neoplasms | |
| 10:30-10:45 |
Alessio Biagioni |
Hypoxia-Induced Extracellular Vesicles Regulate BCR::ABL1 Expression in Chronic Myeloid Leukemia |
| Flash Poster Session |
||
| Poster Presentation | Flash Poster Session | |
| 10:45-10:50 | Waleed Alshukaili Poster Presenter |
Medication Adherence and Health Beliefs Among Patients with Sickle Cell Disease in Oman: A Cross-Sectional Study |
| 10:50-10:55 | Alexander Shatskiy Poster Presenter |
Left Ventricular Aneurysm after MINOCA in Antiphospholipid Syndrome: A Single-Center Cohort Study |
| 10:55-11:00 | Aratrika Halder Poster Presenter |
Transfection strategy for Haematopoietic Stem cells to treat rare blood diseases like Sickle Cell Anaemia |
| 11:00-11:05 | Yasmine Bendimrad Poster Presenter |
Molecular, cytogenetic, and immunophenotypic landscape of de novo acute myeloid leukemia: a Moroccan single-center study |
| 11:05-11:10 | Vira Anatoliyivna Barilka Poster Presenter |
The Role of Transforming Growth Factor Beta 1 in Tumor Microenvironment of Acute Lymphoblastic Leukemia Patients |
| 11:10-11:15 | Abdel Amide Gbadamassi Poster Presenter |
Positive Predictive Value of [18F]FDG PET/CT for the Detection of Bone Marrow Infiltration in Diffuse Large B-Cell Lymphoma: Impact of Focal versus Diffuse Pattern |
| 11:15-11:20 | Frederico Larré Pozzebon Poster Presenter |
Efficacy of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria: A Quantitative Synthesis |
| 11:20-11:25 | Fatima Farhan Poster Presenter |
Accelerated Phase of Chediak–Higashi Syndrome with Hemophagocytic Lymphohistiocytosis (HLH): Insights from a Pediatric Case |
| 11:25-11:30 | Luis Ramalhete Poster Presenter |
Mapping Donor Access for HSCT: Related, Haploidentical, and Unrelated Options in a Portuguese HLA Cohort |
| 11:30-11:35 | Mohammad-Salar Hosseini Poster Presenter |
Mitochondrial glutaminase inhibitor telaglenastat (CB-839) in multiple myeloma: a systematic review of preclinical evidence |
| 11:35-11:40 | Roihan Awg Isa Poster Presenter |
Beyond Physiological Monocytes: Diagnostic Challenges in Infantile AML with KAT6A::CREBBP Fusion |
| 11:40-11:45 |
Sushant Sahu Poster Presenter |
Monitoring Red Blood Cells Agglutination Using Screen-Printed Electrodes: A Multimodal Voltammetric and Impedimetric Study Via Antigen-Antibody Sensing Approach |
| 11:45-14:00 | Break | Break |
S4. Non-Hodgkin Lymphoma and
S5. Hodgkin Lymphoma
Date: 29th October 2026 (Thursday)
Time: 14:00 (CET, Basel) | 09:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time (CET) |
Speaker | Title |
| Session 4. Non-Hodgkin Lymphoma | ||
| 14:00-14:10 |
Prof. Dr. Gerardo Musuraca |
Welcome by Session Chair |
| 14:10-14:40 |
Prof. Dr. Gerardo Musuraca |
Relapse /Refractory Diffuse large B cell lymphoma: The changing algorithm |
| 14:40-15:20 |
|
Classic Hodgkin lymphoma in the age of artificial intelligence and emerging technologies |
| 15:20-15:50 |
Dr. Christina Cox |
Metronomic chemotherapy and targeted therapy in Non-Hodgkin Lymphomas |
| Session 5. Hodgkin Lymphoma | ||
| 15:50-16:00 |
Dr. Alessandra Romano |
Welcome by Session Chair |
| 16:00-16:40 |
Dr. Ana Sureda |
Treatment of Classical Hodgkin's Lymphoma in the Era of Targeted Therapies |
| 16:40-17:10 |
Prof. Dr. Hans Knecht |
The 3D molecular pathogenesis of the diagnostic Reed-Sternberg cell in classical Hodgkin Lymphoma |
S8. Rare Diseases
Date: 30th October 2026 (Friday)
Time: 09:00 (CEST, Basel) | 04:00 (EDT, New York)| 16:00 (CST Asia, Beijing)
| Time (CET) |
Speaker | Title |
|
09:00-09:10 |
Prof. Dr. Daniela Cilloni Session Chair |
Welcome by Session Chair |
| 09:10-09:30 |
Dr. Efthimia Vlachaki |
Recent advances in β-Thalassemia treatment |
| 09:30-09:50 | Prof. Dr. Carmelo Gurnari Invited Speaker |
VEXAS syndrome |
| Contributed Oral Presentations | Session 8. Rare Diseases | |
| 09:50-10:05 |
Rinmi Kasar |
From Genetic Insights to Public Health Action: β-Thalassemia Carrier Screening Among Youths in Delhi NCR |
| 10:05-10:20 |
Manzama Esso Kassang Konzi |
Diverse Hematologic and Molecular Characteristics of Hemoglobin O-Arab in the Moroccan Population: Experience of Mohammed VI National Laboratory of Medical Analysis |
| 10:20-10:35 | Nadjia BENKHIRA Selected Speaker |
Imiglucerase in Type 1 Gaucher Disease: Long-Term Clinical and Pharmacoeconomic Outcomes in Southwestern Algeria |
| 10:35-10:50 | Aleksandra Laguna Selected Speaker |
Atypical Presentation of TERT-Related Dyskeratosis Congenita with Aplastic Anaemia and Cerebral Venous Sinus Thrombosis |
| 10:50-11:05 | Rita Chiaramonte Selected Speaker |
Impact of COVID‑19 Home‑Confinement and Hypomotility in Haemophilic Arthropathy |
| 11:05-14:00 | Break | Break |
S2. Acute Myeloid Leukemia and
S3. Acute Lymphoblastic Leukemia
Date: 30th October 2026 (Friday)
Time: 14:00 (CET, Basel) | 09:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time (CET) |
Speaker | Title |
| Session 2. Acute Myeloid Leukemia | ||
| 14:00-14:10 |
Prof. Dr. Giovanni Martinelli and Dr. Giorgia Simonetti |
Welcome by Session Chairs |
| 14:10-14:30 |
Dr. Giorgia Simonetti |
Acute myeloid leukemia: a metabolic perspective |
| 14:30-15:10 |
Prof. Dr. Attilio Orazi
|
Evolving Paradigms in Acute Myeloid Leukemia Classification: Present Standards and Future Directions |
|
Contributed Oral Presentations |
Session 2. Acute Myeloid Leukemia | |
| 15:10-15:25 |
Luca Collodel |
SPONTANEOUS RH AND ABO TYPE CHANGES AS AN EARLY SIGN OF LOSS OF HETEROZYGOSITY IN ACUTE MYELOID LEUKEMIA |
| 15:25-15:40 | Goktug Ozkan Selected Speaker |
Readability and Action Cue Visibility in Public Patient Education Pages About Acute Myeloid Leukemia |
| S3. Acute Lymphoblastic Leukemia | ||
| 15:40-16:10 |
Prof. Dr. Partow Kebriaei |
The role of allogeneic hematopoietic stem cell transplantation in ALL |
| 16:10-16:40 | Prof. Dr. Veronika Bachanova Keynote Speaker |
Current Concepts in Therapy of Acute Lymphoblastic Leukemia |
| 16:40-17:00 | Dr. Matthew J. Wieduwilt Invited Speaker |
Current frontline therapy options for older patients with newly diagnosed B-cell acute lymphoblastic leukemia |
| Contributed Oral Presentations | S3. Acute Lymphoblastic Leukemia | |
| 17:00-17:15 | Weronika Broszkiewicz Selected Speaker |
Relaxin-2 Preconditioning Promotes Dexamethasone Responsiveness in Molecularly Distinct Glucocorticoid-Resistant T-ALL Models |
| Prof. Dr. Claudio Cerchione Event Chair |
Closing Remarks | |